Vanguard Global Advisers’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Vanguard Global Advisers's AXSM Position: Q3 2026 in Review
Vanguard Global Advisers increased its Axsome Therapeutics (AXSM) stake by 1.4% in Q3 2026, buying an estimated $55.9K and bringing the position to 19,258 shares worth $3.55M. The position accounts for ﹤0.01% of the portfolio, ranked #923.
Vanguard Global Advisers first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.65M in Q2 2026. 459 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Vanguard Global Advisers held 19,258 shares of Axsome Therapeutics worth $3.55M as of Q3 2026.
- Vanguard Global Advisers bought 257 Axsome Therapeutics shares in Q3 2026, an estimated $55.9K.
- Axsome Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #923 holding.
- Vanguard Global Advisers first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Axsome Therapeutics position peaked at $4.65M in Q2 2026.
- 459 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.